The Valley Desk

NCT04439175 · Interventional trial

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Overall registry status Active not recruiting

Phase 2

Conditions Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov